<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01680029</url>
  </required_header>
  <id_info>
    <org_study_id>PM001</org_study_id>
    <nct_id>NCT01680029</nct_id>
  </id_info>
  <brief_title>PBASE-system Acute Migraine Clinical Investigation</brief_title>
  <official_title>A Clinical Investigation to Evaluate the Safety and Performance of the PBASE-system When Used in the Treatment of Acute Migraine Episodes of Moderate to Severe Intensity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chordate Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chordate Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the performance and safety of the PBASE-system when used in the treatment of&#xD;
      acute migraine episodes of moderate to severe intensity. The study will evaluate the effect&#xD;
      of treatment on migraine pain and symptoms during an acute attack and also any long-term&#xD;
      effect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Too slow recruitment rate&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache relief</measure>
    <time_frame>2 hours post-initiation of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>PBASE-system 2.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PBASE-system 2.0</intervention_name>
    <arm_group_label>PBASE-system 2.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent prior to participation in the&#xD;
             clinical investigation&#xD;
&#xD;
          -  Male or female aged between 18 and 65 years&#xD;
&#xD;
          -  Diagnosed as suffering from migraine with or without aura according to IHS&#xD;
             classification (ICHD-II)&#xD;
&#xD;
          -  Reported history of 2 to 6 migraine episodes per month during previous 3 months,&#xD;
             confirmed during a prospective baseline period of one month&#xD;
&#xD;
          -  Reported history of no less than 50% of migraine episodes involving moderate or severe&#xD;
             pain intensity, confirmed during a prospective baseline period of one month&#xD;
&#xD;
          -  Reported history of at least 48 hours of freedom from headache between migraine&#xD;
             attacks, confirmed during a prospective baseline period of one month&#xD;
&#xD;
          -  Reported history of the majority of untreated migraine attack durations lasting 8&#xD;
             hours or more&#xD;
&#xD;
          -  Onset of migraine headache occured before age 50&#xD;
&#xD;
          -  Reported history of migraine for more than one year&#xD;
&#xD;
          -  Able and willing to maintain current preventive headache medication regimen(s) (no&#xD;
             change in type, frequency or dose) from baseline screening visit to 2 weeks&#xD;
             post-treatment&#xD;
&#xD;
          -  Able to understand and complete the electronic diary&#xD;
&#xD;
          -  Experiencing an acute migraine attack of moderate to severe pain intensity at the time&#xD;
             of treatment&#xD;
&#xD;
          -  Treatment is possible within 5 hours of migraine onset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reported history of 15 or more headache days per month (i.e. headaches of any kind),&#xD;
             confirmed during a prospective baseline period of one month&#xD;
&#xD;
          -  Reported frequency of non-migraine headaches exceeding 6 days per month, confirmed&#xD;
             during a prospective baseline period of one month&#xD;
&#xD;
          -  Unable to distinguish between migraine headaches and other headache types at the onset&#xD;
             of a migraine attack&#xD;
&#xD;
          -  Treatment with Botox received within 6 months of the screening visit, or between the&#xD;
             screening and treatment visit&#xD;
&#xD;
          -  Previously treated with an implantable stimulator or any implantable devices in the&#xD;
             head and/or neck&#xD;
&#xD;
          -  Diagnosed as having a pronounced anterior septal deviation&#xD;
&#xD;
          -  History of sinus surgery, transphenoidal surgery for pituitary or other lesions or CSF&#xD;
             rhinorrhea&#xD;
&#xD;
          -  Fitted with a pacemaker /defibrillator&#xD;
&#xD;
          -  Previously treated with radiation to the face&#xD;
&#xD;
          -  Ongoing bacterial infection in the nasal cavity&#xD;
&#xD;
          -  History of nose bleeds (epistaxis)&#xD;
&#xD;
          -  Ongoing malignancy in the nasal cavity&#xD;
&#xD;
          -  Concomitant condition that could cause excessive bleeding&#xD;
&#xD;
          -  Known allergy to polyvinylchloride,the material used for fabrication of the balloon&#xD;
             part of Catheter A100, or medicinal liquid paraffin&#xD;
&#xD;
          -  Concurrent condition or risk of non-compliance that, in the investigator's opinion,&#xD;
             may affect the interpretation of performance or safety data or which otherwise&#xD;
             contraindicates participation in a clinical investigation&#xD;
&#xD;
          -  Any change in migraine prophylaxis between the screening and treatment visit&#xD;
&#xD;
          -  Women of childbearing potential who is pregnant or at risk of becoming pregnant prior&#xD;
             to or during the treatment phase&#xD;
&#xD;
          -  Participation in a clinical research study within 3 months of enrolment or planned&#xD;
             participation at any time during this clinical investigation&#xD;
&#xD;
          -  Considered to meet the definition of vulnerable in the Investigator's opinion&#xD;
&#xD;
          -  Headache or migraine episode within the 48 hours prior to treatment&#xD;
&#xD;
          -  PRN (as required) or acute migraine medication(s) taken within the 48 hours prior to&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stoke-on-trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>September 3, 2012</study_first_submitted>
  <study_first_submitted_qc>September 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2012</study_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01680029
org study id: PM001
nct id: NCT01680029
lead sponsor: 
has dmc: No
To evaluate the performance and safety of the PBASE-system when used in the treatment of
      acute migraine episodes of moderate to severe intensity. The study will evaluate the effect
      of treatment on migraine pain and symptoms during an acute attack and also any long-term
      effect.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Headache relief
time frame: 2 hours post-initiation of treatment
arm group label: PBASE-system 2.0
arm group type: Experimental
intervention type: Device
intervention name: PBASE-system 2.0
arm group label: PBASE-system 2.0
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: No
facility: 
facility: 
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Migraine Disorders